> Notably, about one-third of users stopped taking the medication during the study period.
This isn't always the patient's choice—my insurance/PBM (CVS Caremark) dropped coverage for the GLP-1 that I was taking (Zepbound) and had several rounds of prior-authorization shenanigans over a few months before they approved the previous-generation GLP-1, Wegovy. Now I've had to start the ramp-up of a different medication again, which hurt and stalled progress. Evil.
This isn't always the patient's choice—my insurance/PBM (CVS Caremark) dropped coverage for the GLP-1 that I was taking (Zepbound) and had several rounds of prior-authorization shenanigans over a few months before they approved the previous-generation GLP-1, Wegovy. Now I've had to start the ramp-up of a different medication again, which hurt and stalled progress. Evil.